Introduction
The ability to predict an HIV-1 patient's disease progression rate will provide an ability to deliver a customized treatment plan, for example, by identifying individuals who may benefit from early intervention. HIV-1 Controllers and Progressors exhibit immunophenotypic differences, even early after infection [1] [2] [3] .
However, even within Progressors there exists a large variation in the rate of progression. Although largely disparate CD4 þ T-cell count and plasma HIV-1 viral load (PVL) values can differentiate fast and slow progression to immunodeficiency [4] [5] [6] , no parameters have been identified that address the 'gray zone' of Progressors where CD4
þ T-cell counts and PVL have limited power to predict outcome.
T-cell differentiation status might also correlate with immune protection [1] . In a simian vaccination model, increased CD4
þ central memory T-cell levels were a better predictor of survival than either CD4 þ T-cell count or PVL [10] . However, such an association was not found in HIV-1 patients [2] . Instead, analysis of acute/early infection samples showed strong predictive power for the frequency of proliferating CD8 þ T cells, the frequency of naive and CD127 þ CD8 þ T cells, and CAVL [2] .
CD8
þ T-cell responses are crucial in containing the virus during acute and early infection, and in determining the viral set point [11, 12] . A positive correlation was identified between PVL and the magnitude of total HIV-1-, Env-and Nef-specific CD8 þ T-cell responses [13] . In vaccinated rhesus macaques, higher ex-vivo virus-specific T-cell responses correlated strongly with survival [10] . In a mixed cohort of acute and chronic HIV-1 patients (untreated and treated), increased response quality (i.e. more polyfunctional cells), rather than magnitude or phenotype of HIV-specific CD8 þ T cells, provided a correlate for better prognosis [14] . No conclusive association with protection has been found in either the magnitude or the breadth of HIV-1-specific T-cell responses [15] .
Here we report on the identification of correlates of progression measured early after HIV infection. We specifically evaluated previously identified correlates on cryopreserved blood samples from a well characterized, early HIV-1 infection cohort from São Paulo, Brazil. We also explored the predictive potential of additional T-cell differentiation and activation markers, as well as of T-cell responses directed to different HIV-1-derived peptide pools. Overall, we evaluated a wide breadth of bulk and antigen-specific markers with the goal of identifying potentially clinically useful measures for staging early HIV-1-infected adults.
Results

Patient cohort
Gender distribution and age at diagnosis of HIV-1 infection was comparable between patients maintaining low levels of viremia (Controllers), with progressive disease requiring antiretroviral therapy within 2 years of diagnosis (Fast Progressors), and with progressive disease not requiring antiretroviral therapy within 2 years (Slow Progressors) ( Table 1 ; a full description of the patient cohort can be found in Supplemental Methods, http:// links.lww.com/QAD/A286). Healthy Donors were on average slightly younger (P ¼ 0.035, Wilcoxon signedrank test). Patient samples were obtained within 1 year of HIV-1 diagnosis by Standard Algorithm for Recent HIV Seroconversion (STAHRS). The CD4 þ T-cell counts were lower in all patients compared with Healthy Donors (P < 0.0001, Wilcoxon signed-rank test).
HLA-B Ã 27, B Ã 57, and B Ã 58 are associated with delayed HIV-1 disease progression [16] [17] [18] . Nevertheless, recent studies reported that the virus-specific CD8 þ T-cell responses are better predictors of disease progression than the HLA genotype [19, 20] . In our patients, beneficial HLA types were enriched in Controllers (57%), but also expressed by 23% of Slow Progressors (Table 1) . Coinfection with GB virus type C (GBV-C) has also 698 AIDS 2013, Vol 27 No 5 The threshold of detection sensitivity of most assays was 400 copies/ml with exceptions at 50 copies/ml.
been proposed to correlate with a slower HIV-1 disease progression and to modulate T-cell activation [21] . Interestingly, Progressors had a higher GBV-C prevalence than Controllers, ruling out GBV-C coinfection as a factor for delayed HIV-1 disease progression of Controllers. This is reminiscent of findings showing similar GBV-C prevalence between elite controllers and chronically infected HIV-1 patients [22] . The CCR5D32 mutation, known to confer resistance to HIV-1 [23, 24] , was found in about 10% of study participants (all heterozygous), and distributed equally in the groups (Table 1) .
Cell-associated viral load
To evaluate the potential role of CAVL among CD4 (Fig. 1a) . The total CD4-associated CAVL was computed by summing the frequency-weighted subset CAVL measurements.
Although PVL were not statistically different between Fast and Slow Progressors (Table 1) , CAVL was significantly elevated in Fast Progressors (P ¼ 0.0014, Mann-Whitney; Fig. 1b) . CAVL was lowest in Controllers, and altogether undetectable, by our method, in 42% of this group. This is not surprising as tissues such as lymph nodes and gut are the major viral reservoir [25] ; ultrasensitive CAVL measurements are required to identify peripheral blood mononuclear cell (PBMC)-associated virus in patients with very low viral burden.
Although the total CAVL was significantly different between study groups, the viral burden in Nv CD4
þ T cells was comparable in all study groups (Fig. 1c) , supporting the hypothesis that infection of Nv occurs during homeostatic proliferation of these cells and is not a pathogenic mechanism of HIV-1 infection [26] . Notably, a large fraction of Slow Progressors (39%) and Controllers (42%) had undetectable CAVL in Nv cells, consistent with decreased homeostatic proliferation in the face of decreased CD4
þ T-cell loss [27] . In all other subpopulations examined, Fast Progressors had higher CAVL than Slow Progressors, with the lowest CAVL found in Non-naive Fig. 1 . Cell-associated viral load (CAVL). In the four CD4 þ T-cell subsets sorted by flow cytometry (a) CAVL was quantified by qPCR. All qPCR reactions were performed in duplicate and HIV gag amplification normalized to albumin amplification in parallel aliquots. Total CAVL (b), CAVL in naive (c), and CCR5 þ memory CD4 þ T cells (d) is shown for Fast Progressors (FP), Slow Progressors (SP), and Controllers (C). Measurements from all patients were grouped to compare overall viral burden in the four CD4 þ T-cell subsets (e). The ratio of CAVL in CCR5 À (M R5À ; includes both CCR7 þ and CCR7 À subsets) and CCR5 þ (M R5 ) memory cells was calculated in order to compare the relative viral burden in the two subsets (f). Bars represent medians and standard error means. Dotted lines indicate the threshold of detection for this assay; measurements that fall below this line had no detectable HIV gag, and the distribution of these values provide a conservative estimate of the CAVL in these samples. Statistically significant differences were determined using the Wilcoxon signed-rank test for matched samples, and the Mann-Whitney test for intergroup comparisons; results are indicated by lines above the graphs: solid grey, P < 0.01; dotted black, P < 0.001; solid black, P < 0.0001.
Controllers (Fig. 1d , Suppl. Fig. 1a and b, http:// links.lww.com/QAD/A286). Overall, as expected, M R5 carried the highest and Nv the lowest viral burden among CD4 þ T-cell populations (Fig. 1e) . The distribution was comparable in individual study groups (Suppl. Fig. 1c and d, http://links.lww.com/QAD/A286), except in Controllers where a high frequency of samples had undetectable CAVL (Suppl. Fig. 1e , http://links.lww.-com/QAD/A286). Within Progressors, the viral burden in M R5 was over 1 log higher than in Nv cells from the same patients, whereas within Controllers no such difference was found (Suppl. Fig. 1f , http://links.lww.-com/QAD/A286). In contrast, the relative CAVL between CCR5
þ and CCR5 À memory subsets was similar within each patient group (Fig. 1f ), in agreement with data from nonhuman primates [28] .
CD8
R T-cell differentiation reveals correlates of HIV-1 infection, as well as predictors of rapid and slow disease progression Naive and memory T-cell subsets were defined by differential expression of CD45RO, CCR7, and CD27. This results in eight subpopulations, including naive (
; a more stringent definition of T NV than used for the CAVL analyses), central memory (
, and terminal effector cells (T TE : CD45RO
, as well as three subsets that are not named in the literature. As they most closely resemble T CM , T TM , and T TE (unpublished observation), we refer to these as T CM (Fig. 2b) . Controllers had comparable levels of T TM , T CM Ã , and T TE Ã subsets to Healthy Donors, whereas both groups of Progressors revealed significantly elevated frequencies of T TM and T TE Ã , as well as reduced levels of T CM Ã cells. Interestingly, Controllers had significantly higher frequencies of CD8 þ T TE cells (Fig. 2b) than Progressors or Healthy Donors, potentially the result of an effective early anti-HIV-1 immune response and concomitant inflammation driving a large number of cells into the T TE stage.
No major changes were observed in the memory signatures of CD4 þ T cells from HIV-1-infected individuals compared with Healthy Donors (Suppl. Fig. 2b and c, http://links.lww.com/QAD/A286). This is somewhat surprising, as a reduction in the CD4 þ T-cell count had already taken place ( Table 1) .
The frequency of CD38
R CD8 R T cells is a strong predictor of disease progression within the first year after HIV-1 infection The activation status of both CD4 þ and CD8 þ T cells was investigated by analyzing the expression of several cell surface markers associated with activation and differentiation, as well as the intracellular lytic molecule Granzyme B and the nuclear proliferation marker Ki67 (Fig. 2c) . Some antigens (CD25 and CD57 on CD4 þ T cells; CD38 and CD57 on CD8 þ T cells) were elevated in all HIV-1-infected groups compared with healthy controls, possibly resulting from the systemic inflammation accompanying HIV-1-infection. Other markers (CD38 and Ki67 on both CD4 þ and CD8 þ T cells) were elevated in Progressors as compared with Controllers ( Fig. 2d and e) , reflecting even higher activation levels in these patients. No differences were found between Fast and Slow Progressors.
Elevations in both the frequency [7] and median fluorescence intensity (MFI) [4, 8, 9] , a measure of the average molecular density of a given Ag at the cell surface, of the ectoenzyme CD38 on CD8 þ T cells have long been correlated with a poor prognosis in HIV infection. Indeed, although all patient groups had significantly elevated frequencies of CD38 þ CD8 þ T cells compared with Healthy Donors, the proportion of CD38 þ cells among CD8
þ T cells was 10-fold higher in Progressors than Controllers, with no overlap between these groups. Although significantly different between Progressors, Controllers, and Healthy Donors, the MFI of CD38 on CD8 þ T cells did not provide such a clear-cut distinction (Fig. 2f) . Furthermore, although all CD4 þ and CD8
þ T-cell subsets demonstrated elevated MFI of CD38 in HIV-1-infected individuals, the differences were much less pronounced for very early and very late differentiation stages (Suppl. Fig. 3a and b, http://links.lww. com/ QAD/A286).
As the Controllers from our cohort were defined as maintaining PVL less than 2000 copies/ml, with no overlap in PVL between Controllers and Progressors, and the frequency of CD38 þ CD8 þ T cells had previously been shown to correlate with plasma viremia [29] , this parameter alone was sufficient to segregate Progressors and Controllers in our study of early infection samples.
Increased differentiation of HIV-1-reactive cells indicates poor prognosis As CD8
þ T-cell responses are key in containing the virus during acute and early infection [11, 30] , we hypothesized that some characteristic of the HIV-1-specific T-cell responses might have prognostic value. However, the total magnitude [interferon-g (IFN-g), tumor necrosis factor (TNF), and/or interleukin-2 (IL-2)] of the HIV-1-specific CD4
þ and CD8 þ T-cell responses, measured after stimulating with HIV-1-derived peptide pools for Env, Gag, Nef, Pol, or TatþRevþVprþVpu (TRVV), was not statistically different between patient groups (Fig. 3a) . Similarly, there was no statistically significant difference between groups in the absolute frequency of CD4 þ T cells reactive to any of the HIV-1 peptide pools tested (Suppl. Fig. 4a , http://links.lww.com/QAD/ A286). Within CD8 þ T cells, there was a trend for more elevated Env-and lower Nef-specific response magnitudes in Fast Progressors, but these did not prove statistically significant (Suppl. Fig. 4b , http://links.lww.-com/QAD/A286).
However, significant differences in the scope of the response (i.e., which HIV-1 proteins were targeted) occurred between patient groups (Suppl. Fig. 4c , http:// links.lww.com/QAD/A286). On average, close to half of the HIV-1-specific CD8 þ T cells of Controllers were Gag-specific, significantly more than either in Fast (P ¼ 0.017, Wilcoxon signed-rank test) or Slow Progressors (P ¼ 0.004, Wilcoxon signed-rank test). In contrast, Progressors demonstrated more diversity in þ T cells in the three HIV-1-infected study groups and Healthy Donors, as defined by expression patterns of CD45RO, CCR7, and CD27. Nv, naive; CM, central memory; TM, transitional memory; EM, effector memory; TE, terminal effector; CM Ã , TM Ã , TE Ã are phenotypically defined populations that are not described in the literature, but that arise by this gating scheme; their activation phenotype and cytokine potential most closely resembles that of T CM , T TM , and T TE , respectively, hence their nomenclature. (c) The activation phenotype of CD4 þ and CD8 þ T cells was determined using the gating illustrated. As the threshold for CCR5 detection differed between CD57 þ and CD57 À cells, two separate gates were set and concatenated to evaluate the total frequency of CCR5 þ cells. Activation phenotype of CD4 þ (d) and CD8 þ T cells (e). The median fluorescence intensity (MFI) of CD38 was determined for CD38 þ cells (f). Bars indicate medians and boxes interquartile ranges. P-values below 0.01 are reported for pies, as calculated by a permutation test. For the bar charts, groups were compared using a Wilcoxon signed-rank test, and statistically significant differences are indicated by color-coded bars: grey, P < 0.01; black, P < 0.001. the targeted HIV-1 proteins (Suppl. Fig. 4c , http:// links.lww.com/QAD/A286). Fast Progressors exhibited a higher proportion of Env-specific cells compared with Slow Progressors, in agreement with a report that early Env-specific responses might be more prevalent in patients with higher PVL [20] . Finally, we found Slow Progressors to have a larger proportion of Nef-specific cells than Controllers.
The cytokine pattern of total HIV-reactive cells differed significantly between groups (Fig. 3b) , with Slow Progressors exhibiting a cytokine pattern more similar to Controllers among CD4 þ T cells, but more like Fast Progressors among CD8 þ T cells. We investigated the frequency of subsets producing either of the possible cytokine combinations in response to individual HIV-1 peptide pools. Few statistically significant differences were observed, although a pattern emerged wherein increases in the frequency of CD8 þ T cells producing only TNF correlated with poor prognosis, whereas increases in Gagspecific CD8
þ T cells producing IFN-g and IL-2 in the presence or absence of TNF correlated with a better prognosis (Fig. 3c) .
CD57
þ cells were less frequent within total HIV-1-reactive CD4 þ T cells from Controllers, whereas CD127 þ and Programmed Death-1 þ (PD-1 þ ) cells were more prevalent (Fig. 3d) . Their CD8 þ counterparts were more likely to express CD28 and PD-1 than within Progressors (Fig. 3d) . Most of these patterns were also found in cytokine þ cells after stimulation with individual HIV-1-derived peptide pools (Fig. 3e) , indicating that the activation and differentiation phenotypes of HIV-1-reactive T cells are independent of the targeted Ag. Although fewer statistically significant differences were observed in the proportion of T-cell differentiation subsets within cytokine þ CD4 þ or CD8 þ T cells, cells from Controllers had higher proportions of less differentiated cells, whereas more differentiated cells were more prevalent in Progressors (Fig. 3f) .
Early prediction of disease progression
Even within the first year of HIV-1 infection, immunophenotypic analysis of peripheral blood T cells can provide an indication of subsequent disease progression within individual patients. Although the frequency of CD38 þ CD8 þ T cells alone is sufficient to segregate Progressors from Controllers (Figs. 2e and 4) , no such major differences were observed between Fast and Slow Progressors in any one parameter. We tested the power of previously identified correlates of HIV-1 disease progression to distinguish either between Controllers and Progressors (Fast and Slow Progressors combined) or between Fast and Slow Progressors from our patient cohort (Supplementary Table 1 , http://links.lww.com/ QAD/A286). A number of those correlates, namely PVL and CAVL (the former being part of the selection criteria in the present cohort), as well as T-cell activation (frequency of CD38 þ and Ki67 þ cells, molecular density of CD38 per cell), proved useful markers to predict outcome between Controllers and Progressors. However, neither CD4 þ T-cell counts nor the proportions of CD4 þ T CM , CD8 þ T NV , or CD127 þ CD8 þ T cells were significantly different between patient groups at this early time point. None of the previously identified correlates were significantly different between Fast and Slow Progressors, with the exception of CAVL.
As no single parameter was able to differentiate between Fast and Slow Progressors in the absence of differences in CD4 þ T-cell count or PVL, we explored multivariate prediction using a classification tree. With the goal of developing a prediction rule based on parameters that would be feasible to assess in a clinical setting, we excluded the cytokine data from this analysis (indeed, including the cytokine data did not increase the power of this analysis). A multistep prognostic tool was established that predicts 2-year outcome based on clinically measured parameters early after infection (Fig. 4) . As in previous studies [2, 5] , among the progressors CAVL proved to be the strongest predictor, with a total CAVL of 9.0 Â 10
À4
gag copies/cell chosen as the threshold. Ninety-five percent (19/20) of patients who had a CAVL below this threshold were categorized as Slow Progressors. For patients with a CAVL of at least 9.0 Â 10 À4 gag copies/ cell, our model uses a subsequent threshold of 43% CCR5 þ CD8 þ T cells, with a high value on both of these variables predicting slow progression. Patients with a low value on % CCR5 þ CD8 þ T cells among those who had elevated CAVL were predicted as Fast Progressors.
The present decision tree analysis shows that even early after HIV-1 infection when CD4 þ T-cell counts are not predictive for disease progression and PVL also fails to differentiate between Fast and Slow Progressors, relatively few additional parameters can be employed to determine individualized patient follow-up schedules and treatment regimens. As both the frequency of CD38 expressing CD8 þ T cells and CAVL had already previously been identified as important measurements that can be used to predict outcome, only the relevance of CCR5 þ CD8 þ T cells within Progressors with elevated CAVL would need to be confirmed in an independent study.
Discussion
Predicting the rate of progression to immunodeficiency after HIV-1 infection is an important challenge in clinical research. Understanding the mechanisms involved in spontaneous viral control provides an informed selection of milestones in patient follow-up, including the important decision of when to commence antiretrovirals. In this retrospective study, we assessed several immune and viral markers in a well characterized cohort of HIV-1-infected individuals from whom early samples had been collected prospectively, to identify surrogate markers for protection or development of immunodeficiency. Our analysis yielded a rich dataset for both CD4 þ and CD8 þ T cells, including three functional and 12 phenotypic parameters, in addition to the CAVL measurements (CD4 þ T cells only).
In concert with previous findings [7] , the frequency of CD8 þ T cells expressing CD38 proved to be a very strong predictor of disease progression, and in itself was sufficient to distinguish between Progressors and Controllers. This is likely linked [29] to the differences in PVL between Progressors and Controllers in our patient cohort. In addition to being a useful phenotypic marker, such CD38 þ CD8 þ T cells from HIV-1-infected individuals with high levels of CD38 þ CD8 þ T cells have been shown to express higher levels of CD95 and to be more susceptible to both spontaneous and FasL-mediated apoptosis [29] , which could in part explain the reduced CD8 þ T-cell-mediated viral control in such patients.
As in previous studies [26] , we detected HIV gag DNA in all CD4
þ T-cell subsets investigated, including T NV cells. Interestingly, there was no difference between patient groups in the CAVL in T NV cells, though the fraction of patients with HIV gag DNA þ T NV cells increased with , and (f) no statistically significant differences were observed between Fast and Slow Progressors, with the exception that the frequency of T TE was slightly more elevated (P ¼ 0.042) in Slow Progressors compared with Fast Progressors. FP, Fast Progressors; SP, Slow Progressors; C, Controllers; TRVV, TatþRevþVifþVpr. For bar charts (Wilcoxon signed-rank test) and pies (permutation test), statistically significant differences are indicated by lines above the graphs: dotted grey, P < 0.05; solid grey, P < 0.01; dotted black, P < 0.001. more rapid disease progression. Although CCR5 is a coreceptor for HIV-1 and its expression is obligate for invitro infections with transmitted viruses, there is still substantial viral burden among nominally CCR5 -cells. T NV , which express no CCR5 [31] , have substantially lower but easily detectable CAVL. Among memory cells, CCR5 -cells also carry substantial viral genomes. Although this might be a consequence of CCR5 downregulation following infection, we have shown that memory cells that have too little CCR5 expression to be detected by immunophenotyping still express CCR5 mRNA [28] .
Previously, T CM were reported to carry the highest viral burden [26, 32] ; however, we detected little difference in the CAVL between CCR5 À CCR7 þ CD45RO þ and the more differentiated CCR5 À CCR7 À CD45RO þ memory cells. Both these subsets had a lower viral content than CCR5 þ CD45RO þ memory cells. We found no difference in predictive power of CAVL within any subset (vs. total), suggesting that the relative seeding of the different subsets measured here, though biologically important, is not clinically relevant. Notably, out of all the parameters investigated in the present study, the total CAVL proved to be the strongest correlate of progression in Progressors, for whom CD4 þ T-cell counts and PVL fail to predict outcome.
No differences were observed in the total HIV-1-specific response magnitude between Progressors and Controllers, similar to a previous report [33] . However, cytokine responses of Controllers were more polyfunctional, comprising fewer cells producing one cytokine only. Additionally, the phenotype of CD4 þ and CD8 þ HIV-1-specific T cells differed significantly between Controllers and Progressors, cytokine þ cells from Progressors being more likely to express CD57. Among cytomegalovirus (CMV)-specific CD8 þ T cells, those lacking CD57 expression appear to exert a more protective effect against CMV in stem cell transplant recipients [34] . A larger proportion of CD4 þ T cells from Controllers expressed CD127 or PD-1, indicating a potential difference in longevity of HIV-1-reactive cells between patient groups.
A larger fraction of the total HIV-1 cytokine response was directed against Gag in Controllers, while Slow Progressors had a larger proportion of Nef-specific cells than Controllers, and Fast Progressors had a larger proportion of Env-specific cells than Slow Progressors. As Nef-specific responses are developed earlier than A decision tree was created using the Rpart function in R to predict patient group assignment by iteratively choosing the parameter with strongest predictive capacity out of all potential variables at every step. All cell-associated viral load (CAVL) and phenotypic parameters [i.e. T-cell differentiation and activation, median fluorescence intensity (MFI) of CD38 on total and subsets of T cells] were included in the analysis. Cutoff values for decision-determining parameters were software-determined and are noted in the tree. Values in parentheses indicate the proportion of a given group falling into the respective leaf of a tree. The cross-validated prediction accuracy for predicting individual patient groups was 92% for Fast Progressors, 85% for Slow Progressors and 100% for Controllers, with an overall prediction accuracy of 90% (P < 0.001). As the difference in the immunophenotypes between Controllers and Progressors could drive the model's predictive potential, we repeated the permutation test including only Fast and Slow Progressors in the model, and found that the model still held, with a P-value of 0.002. Red dots, Fast Progressors (FP); blue dots, Slow Progressors (SP); green dots, Controller (C); <, values lower than cutoff value; !, values equal to or higher than cutoff value.
Gag-specific responses during the course of HIV-1-infection [20, 35] , early Gag-specific T-cell responses reflect a faster maturation of the anti-HIV-1 response and may thereby indicate a favorable prognosis.
Burgers et al. [1] found that elevated proportions of T CM and T INT (corresponding to T TM and T TE Ã in our study), and T EM within total and HIV-specific CD8 þ T cells, correlated with a lower and higher viral set point, respectively. Our data do not confirm these findings, although discrepancies could be due to differences in sampling time points, subset definitions, origin and demographics of study populations, and viral subtypes (Clade B vs. Clade C). In our cohort, the differentiation pattern of CD8 þ T cells largely mimicked that of Healthy Donors, apart from a much more elevated proportion of T TE , balanced by reduced fractions of T NV and T CM . In comparison to HIV-1 Controllers, Progressors demonstrated higher proportions of T CM (comparable to Healthy Donors), T TM and T TE Ã , together with lower frequencies of T CM Ã and T TE (comparable to Healthy Donors). Although no differences were observed in the differentiation phenotypes of Fast and Slow Progressors, the above observations provide valuable reference phenotypes for vaccine trials.
We are currently analyzing the longitudinal development of T-cell phenotypes and functionality in these patients (Mahnke et al., in preparation). This will allow us to correlate measurements made at an early time point with immunopathogenesis (rather than just clinical progression as reported here). In addition, the longitudinal analyses may reveal whether rates of change in biomarkers are clinically predictive. Although less practical (in that multiple measurements over months or years are needed), such assessments may provide more powerful correlates.
Our data demonstrate that even early after HIV-1 infection, where CD4 þ T-cell counts and PVL do not serve as predictive parameters, the CAVL and immunophenotype of CD8 þ T cells can be used as predictive correlates. We propose that a few additional parameters be measured in the clinic during early HIV-1 infection, namely CAVL, the frequency of CD38 þ and CCR5 þ CD8 þ T cells, to attempt an early prediction of disease progression. These measurements enable a preemptive, individualized follow-up and ARV treatment program.
